For the past year and a half, management considered a more aggressive capital structure, and they recently announced a plan to add leverage to the balance sheet while using the proceeds for
a large share repurchase program.
Jim Cramer highlights
large share repurchase programs at Apple, Boeing and others in a market that's grown sour on buybacks.
Since 2012, when the company launched
the largest share repurchase program ever, Apple has returned a little more than $ 100 billion to shareholders in stock buybacks and dividends.
The iPhone maker's plan to return up to $ 100 billion to its shareholders marks
the largest share repurchase program announced this year.
As such, the Company is one of the largest dividend payers in the world and has
the largest share repurchase authorization in history.
Beyond this,
large share repurchases mean the dividend will pose less of a strain in the future, as the shares outstanding are reduced.
First were
the large share repurchases.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a
larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market
share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its
share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Separately, Bill Gross, manager of the world's
largest mutual fund, said in a Twitter posting that Icahn should stop pushing Apple for additional
share repurchases and do more for charitable causes.
Among the
largest U.S. defense contractors, Northrop Grumman Corp has spent more than $ 12 billion on
share repurchases since 2010, even as revenue has declined in each of the past five years.
We thank you for being receptive to us and other
large shareholders, all of whom are investment professionals offering advice concerning an investment decision, as the decision to
repurchase shares is in effect the company making an investment in itself.
These
share repurchases have been funded in part by a $ 17 billion debt offering, the
largest ever as of the time of issuance.
It is our understanding that you solicited feedback from various
large shareholders concerning our previous request, but we don't think anyone would deny that we were a key influence with respect to your previous decision to increase
share repurchases.
Except for a short interlude in 2008 - 09,
share repurchases have been very
large since the early 2000s.
Second, management would have to pay out
large dividends or undertake substantial
share repurchases.
In fact, should the
share repurchases grow
large enough, it's possible that a perfectly healthy, prosperous company could have a negative stated net worth and appear to be leveraged to the hilt!
«But either
share repurchases or dividends will keep [Berkshire's cash pile] from growing
larger and
larger and
larger,» Brandt said.
``... We look forward to the capital return program update in April, anticipating it will include a
large increase to
share repurchases,» Icahn wrote.
For these companies, the
share repurchase was almost as meaningful as a
large acquisition.
The reason we chose Apache (APA) and Chesapeake (CHK) from a
large pool of undervalued energy stocks was that both managements had shown a willingness to sell assets and redeploy the proceeds by
repurchasing shares.
To the extent that aggregate short exposure exceeds the number of
Shares available for purchase (for example, in the event that
large redemption requests by Authorized Participants dramatically affect
Share liquidity), investors with short exposure may have to pay a premium to
repurchase Shares for delivery to
Share lenders.
As I wrote last year, the 500
largest U.S. companies
repurchased about a quarter of their equity's dollar value from 1998 to 2012, but the number of
shares outstanding actually grew more than 7 % over that same period.
With every month that goes by, management risks missing the window of value for
large - scale & opportunistic
share repurchases.
An active
share repurchase program powered the
large EPS increase — Valspar purchased 4.7 million of its
shares in 2014.
Hi, Shareholders equity is negative due to the
large amount of
share repurchases.
He advises a broad range of financial and corporate clients on the structuring, negotiation and execution of various equity - linked transactions, including public and private convertible debt and preferred stock issuances and associated derivative transactions, accelerated
share repurchase programs, registered forward sale transactions, margin loan transactions in respect of
large stakes in publicly traded companies, and equity - linked hedging and monetization transactions.